Literature DB >> 11502203

Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.

H H Petersen1, M Hansen, S L Schousboe, P A Andreasen.   

Abstract

We localized the epitopes for several murine mAbs to human urokinase-type plasminogen activator (uPA) by Ala scanning mutagenesis and related the localization to the effects of the mAbs on the molecular interactions of uPA. Several antibodies against the serine proteinase domain (SPD) were found to have overlapping epitopes composed of variable combinations of Arg178, Arg179, His180, Arg181, Tyr209, Lys211, and Asp214 in the so-called 37-loop and 60-loop, located near the active site and taking part in the binding of uPA to plasminogen activator inhibitor-1 (PAI-1). Besides inhibiting uPA-catalysed plasminogen activation, all antibodies to SPD strongly delayed the binding of uPA to PAI-1, decreasing the second-order rate constant 15- to 6500-fold. There was no correlation between the relative effects of the 37-loop and 60-loop substitutions on the second-order rate constant and on the binding of the antibodies, indicating that the antibodies did not delay complex formation by blocking residues of specific importance for the uPA-PAI-1 reaction, but rather by steric hindrance of the access of PAI-1 to the active site. The affinity of the SPD antibodies for the uPA-PAI-1 complex was only slightly lower than that for free uPA, indicating that the 37-loop and 60-loop are exposed in the complex. The epitopes for two antibodies to the kringle included Arg108, Arg109, and Arg110. The ability of these antibodies to block the binding of uPA to polyanions correlated with a reduced uPA-polyanion affinity after substitution of the three Arg residues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502203     DOI: 10.1046/j.1432-1327.2001.02365.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  22 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition.

Authors:  Christopher J Farady; Pascal F Egea; Eric L Schneider; Molly R Darragh; Charles S Craik
Journal:  J Mol Biol       Date:  2008-05-11       Impact factor: 5.469

3.  Porphyromonas gingivalis-derived RgpA-Kgp Complex Activates the Macrophage Urokinase Plasminogen Activator System: IMPLICATIONS FOR PERIODONTITIS.

Authors:  Andrew J Fleetwood; Neil M O'Brien-Simpson; Paul D Veith; Roselind S Lam; Adrian Achuthan; Andrew D Cook; William Singleton; Ida K Lund; Eric C Reynolds; John A Hamilton
Journal:  J Biol Chem       Date:  2015-05-15       Impact factor: 5.157

Review 4.  Mechanisms of macromolecular protease inhibitors.

Authors:  Christopher J Farady; Charles S Craik
Journal:  Chembiochem       Date:  2010-11-22       Impact factor: 3.164

5.  Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.

Authors:  Agnieszka Jendroszek; Jeppe B Madsen; Andrés Chana-Muñoz; Daniel M Dupont; Anni Christensen; Frank Panitz; Ernst-Martin Füchtbauer; Simon C Lovell; Jan K Jensen
Journal:  J Biol Chem       Date:  2019-01-16       Impact factor: 5.157

6.  Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Authors:  Kenneth A Botkjaer; Elena I Deryugina; Daniel M Dupont; Henrik Gårdsvoll; Erin M Bekes; Cathrine K Thuesen; Zhuo Chen; Zhou Chen; Michael Ploug; James P Quigley; Peter A Andreasen
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

7.  The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1).

Authors:  Christopher J Farady; Jeonghoon Sun; Molly R Darragh; Susan M Miller; Charles S Craik
Journal:  J Mol Biol       Date:  2007-04-04       Impact factor: 5.469

8.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

9.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

10.  Structural insight into distinct mechanisms of protease inhibition by antibodies.

Authors:  Yan Wu; Charles Eigenbrot; Wei-Ching Liang; Scott Stawicki; Steven Shia; Bin Fan; Rajkumar Ganesan; Michael T Lipari; Daniel Kirchhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.